CRL vs TMO vs IQV Stock Comparison

Charles River Laboratories International, Thermo Fisher Scientific and Iqvia Holdings Prices as of Nov 13, 2026 Peers: Industry group
IQV Iqvia Holdings Inc.
$264.96 +1.1% 1M +18.5% 1Y
Market cap
$43.70B
P/E
31.4x
Revenue (TTM)
$17.31B
Div. yield
–
Contract Research Healthcare
5 wins

Head to Head

11 decided of 12

Thermo Fisher Scientific leads on 5 of the 12 questions below (Thermo Fisher Scientific 5, Iqvia Holdings 5, Charles River Laboratories International 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCRLTMOIQVLeader
Larger companyMarket capitalisation $16.01B $255.60B $43.70B TMO
Cheaper on earningsLower P/E, profitable companies only 398.5x 36.1x 31.4x IQV
Cheaper on forward earningsLower price / next fiscal year consensus EPS 30.8x 27.0x 21.8x IQV
Faster revenue growthRevenue growth, trailing twelve months -1.2% +8.3% +8.8% IQV
More profitableNet margin, trailing twelve months 1.0% 14.9% 8.1% TMO
Better return on capitalReturn on invested capital 0.0% 8.0% 8.2% IQV
Less leveragedLower net debt / EBITDA 5.1x 3.1x 3.9x TMO
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +99.8% +20.7% +18.5% CRL
Better 5-year returnAnnualised price return, 5 years -2.6%/yr +2.0%/yr +0.8%/yr TMO
Less volatileAnnualised volatility, 1 year 47.6% 30.7% 40.8% TMO
Higher overall scoreMean of the five percentile scores vs peers 54/100 60/100 71/100 IQV

Percentile Scorecard

CRLTMOIQV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCRLTMOIQV
Valuation 70 #4 of 11 62 #94 of 243 80 #3 of 11
Growth 10 #10 of 11 41 #136 of 228 60 #5 of 11
Profitability 70 #4 of 11 82 #40 of 222 90 #2 of 11
Financial Health 50 #7 of 13 31 #172 of 248 25 #10 of 13
Shareholder Returns 71 #3 of 8 82 #29 of 158 100 #1 of 8
Overall 54 60 71
  • CRL ranked among 13 companies in Pharma Services
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • IQV ranked among 13 companies in Pharma Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCRLTMOIQVSPY
1 month +12.0%+4.0%+1.1% -2.0%
3 months +20.7%+19.1%+11.9% -2.8%
6 months +124.1%+59.7%+56.7% +2.0%
Year to date +69.5%+20.8%+17.5% +10.6%
1 year +99.8%+20.7%+18.5% +12.2%
3 years +89.5%+52.5%+32.2% +68.1%
3 years, per year +23.8%+15.1%+9.7% +18.9%
5 years -12.4%+10.2%+4.0% +61.4%
5 years, per year -2.6%+2.0%+0.8% +10.1%
10 years +353.0%+362.9%+243.5% +248.5%
10 years, per year +16.3%+16.6%+13.1% +13.3%

Risk

MeasureCRLTMOIQVSPY
Volatility, 1Y 47.6%30.7%40.8% 13.6%
Downside volatility, 1Y 44.7%29.2%39.9% 13.9%
Beta vs S&P 500, 1Y 1.270.710.71 1.00
Return / volatility, 1Y 2.100.670.45 0.90
Max drawdown, 5Y -74.7%-41.5%-51.5% -25.4%
From 52-week high -10.1%-3.0%-5.2% -3.2%
52-week high $375.83$721.63$279.38 $779.14
52-week low $149.93$438.34$156.66 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCRLTMOIQV
P/E now vs peer median 402.1xmedian 34.7x 36.6xmedian 26.5x 31.3xmedian 34.7x
P/S now vs peer median 4.1xmedian 2.5x 5.5xmedian 2.7x 2.5xmedian 2.5x
EV/EBITDA now vs peer median 41.5xmedian 29.1x 25.5xmedian 18.4x 16.6xmedian 29.1x
P/FCF now vs peer median 40.5xmedian 21.0x 34.2xmedian 25.4x 21.0xmedian 21.0x
P/B now vs peer median 5.0xmedian 1.6x 4.7xmedian 2.5x 6.4xmedian 1.6x
PEG now vs peer median -6.49median 1.98 4.84median 0.98 2.71median 1.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCRLTMOIQV
Revenue $3.98B $47.35B $17.31B
Gross profit $1.33B $19.45B $5.72B
Operating income $158.98M $8.47B $2.22B
Net income $39.65M $7.09B $1.40B
Free cash flow $399.63M $7.60B $2.08B
R&D – $1.40B –
EPS (diluted) $0.83 $19.06 $8.35
Cash & equivalents $200.38M $5.46B $2.25B
Total debt $2.44B $41.37B $16.07B
Shares (diluted) 48.58M 371.00M 167.00M
Enterprise value $15.22B $232.12B $34.96B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCRLTMOIQV
P/E 402.1x 36.6x 31.3x
P/FCF 40.5x 34.2x 21.0x
P/Operating cash flow 26.0x 27.8x 16.0x
P/S 4.1x 5.5x 2.5x
P/B 5.0x 4.7x 6.4x
P/Tangible book 5.4x 7.1x 21.3x
EV/EBITDA 41.5x 25.5x 16.6x
EV/EBIT 115.9x 34.8x 25.8x
EV/Revenue 4.6x 6.2x 3.3x
EV/FCF 46.1x 38.8x 27.6x
EV/Operating cash flow 29.6x 31.6x 20.9x
PEG (3Y EPS CAGR) -6.49 4.84 2.71

Growth

14 metrics
MetricCRLTMOIQV
Revenue growth (1Y) -1.2% 8.3% 8.8%
Revenue CAGR (3Y) -1.9% 2.9% 5.2%
Gross profit growth (1Y) 2.1% 7.8% 6.6%
Gross profit CAGR (3Y) -4.8% 4.0% 3.4%
Operating income growth (1Y) 12.8% 12.8% 1.7%
Operating income CAGR (3Y) -37.4% 7.2% 6.2%
Net income growth (1Y) 149.8% 7.9% 9.0%
Net income CAGR (3Y) -56.5% 6.2% 7.8%
EPS growth (1Y) 149.0% 9.7% 11.7%
EPS CAGR (3Y) -61.9% 7.6% 11.5%
Operating cash flow growth (1Y) -17.0% 21.9% -2.4%
Operating cash flow CAGR (3Y) -3.7% 4.5% 11.7%
Free cash flow growth (1Y) -26.5% 24.3% -6.0%
Free cash flow CAGR (3Y) 2.7% 5.1% 16.3%

Profitability

14 metrics
MetricCRLTMOIQV
Gross margin 33.3% 41.1% 33.1%
EBITDA margin 11.2% 24.4% 20.0%
Operating margin 4.0% 17.9% 12.8%
Pretax margin -2.5% 16.7% 9.0%
Net margin 1.0% 14.9% 8.1%
FCF margin 10.0% 16.0% 12.0%
Operating cash flow margin 15.7% 19.7% 15.8%
Return on equity 1.4% 13.2% 21.4%
Return on assets 0.6% 6.2% 4.6%
Return on invested capital 0.0% 8.0% 8.2%
Return on capital employed 2.5% 8.5% 9.9%
Asset turnover 0.5x 0.4x 0.6x
Cash conversion (OCF / net income) 15.7x 1.3x 2.0x
Stock comp / revenue 2.0% 0.7% 1.8%

Financial Health

11 metrics
MetricCRLTMOIQV
Debt / assets 32.8% 36.2% 52.7%
Debt / equity 0.8x 0.8x 2.4x
Net debt / EBITDA 5.1x 3.1x 3.9x
Debt / FCF 6.1x 5.4x 7.7x
Liabilities / assets 56.6% 52.1% 77.7%
Equity / assets 43.4% 47.9% 22.3%
Interest coverage 1.5x 12.0x 2.8x
Current ratio 1.4x 1.8x 0.8x
Quick ratio 0.9x 1.2x 1.0x
Cash ratio 0.2x 0.4x 0.3x
Altman Z-score 3.30 4.18 2.24

Shareholder Returns

7 metrics
MetricCRLTMOIQV
Dividend yield – 0.3% –
Net buyback yield 1.8% 1.6% 2.8%
Shareholder yield 1.8% 1.8% 2.8%
Payout ratio (earnings) – 9.5% –
Payout ratio (FCF) – 8.9% –
Dividend growth (1Y) – 8.0% –
Dividend CAGR (3Y) – 10.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCRLTMOIQV
Forward P/E 30.8xFY2026 27.0xFY2026 21.8xFY2026
EPS, next fiscal year $10.99FY2026 $25.92FY2026 $12.16FY2026
EPS growth, next FY +6.9%FY2026 +13.3%FY2026 +2.0%FY2026
EPS growth, the year after +20.7% +2.2% +11.4%
Revenue, next fiscal year $3.85BFY2026 $50.12BFY2026 $18.65BFY2026
Revenue growth, next FY -4.2%FY2026 +12.5%FY2026 +14.4%FY2026
Revenue growth, the year after +1.2% -2.7% -3.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCRLTMOIQV
Held by institutions 100.0% 90.2% 94.1%
Institutions holding 571 2,627 1,085
Change in shares held, QoQ -0.7% +0.8% +0.3%
Institutions buying 271 1,145 532
Institutions selling 204 1,145 424
Buyers to sellers 1.33 1.00 1.25

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CRLTMOIQV
CRL 1.00 0.65 0.70
TMO 0.65 1.00 0.67
IQV 0.70 0.67 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CRL, TMO and IQV?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Charles River Laboratories International (CRL) $16.01B, Thermo Fisher Scientific (TMO) $255.60B, Iqvia Holdings (IQV) $43.70B.

Which stock is cheaper, CRL, TMO and IQV?

Iqvia Holdings (IQV) trades on the lowest price-to-earnings ratio (Charles River Laboratories International (CRL) 398.5x, Thermo Fisher Scientific (TMO) 36.1x, Iqvia Holdings (IQV) 31.4x). On next year's consensus earnings, Iqvia Holdings (IQV) is cheapest (Charles River Laboratories International (CRL) 30.8x, Thermo Fisher Scientific (TMO) 27.0x, Iqvia Holdings (IQV) 21.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Iqvia Holdings (IQV) grew revenue fastest over the trailing twelve months: Charles River Laboratories International (CRL) -1.2%, Thermo Fisher Scientific (TMO) +8.3%, Iqvia Holdings (IQV) +8.8%.

Which company is more profitable?

Thermo Fisher Scientific (TMO) has the highest net margin (Charles River Laboratories International (CRL) 1.0%, Thermo Fisher Scientific (TMO) 14.9%, Iqvia Holdings (IQV) 8.1%). On return on invested capital, Iqvia Holdings (IQV) leads (Charles River Laboratories International (CRL) 0.0%, Thermo Fisher Scientific (TMO) 8.0%, Iqvia Holdings (IQV) 8.2%).

Which stock has performed better?

Over the past year Charles River Laboratories International (CRL) returned the most: Charles River Laboratories International (CRL) +99.8%, Thermo Fisher Scientific (TMO) +20.7%, Iqvia Holdings (IQV) +18.5%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Charles River Laboratories International (CRL) -2.6%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr, Iqvia Holdings (IQV) +0.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Charles River Laboratories International (CRL) 0.00%, Thermo Fisher Scientific (TMO) 0.00%, Iqvia Holdings (IQV) 0.00%. Charles River Laboratories International (CRL) and Iqvia Holdings (IQV) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Charles River Laboratories International (CRL) 47.6%, Thermo Fisher Scientific (TMO) 30.7%, Iqvia Holdings (IQV) 40.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CRL, TMO and IQV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.